J9019 — Injection, asparaginase (erwinaze), 1,000 iu
J9019 is a HCPCS Level II code for injection, asparaginase (erwinaze), 1,000 iu. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on December 31, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated J9019 on December 31, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J9019
- Long descriptor
- Injection, asparaginase (erwinaze), 1,000 iu
- Short descriptor
- Erwinaze injection
- Added
- January 1, 2013
- Terminated
- December 31, 2025
- BETOS
- O1D
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J9019
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9019 is not quite right, the correct code is very often within a few positions of it.
- J8705Topotecan, oral, 0.25 mg
- J8999Prescription drug, oral, chemotherapeutic, nos
- J9000Injection, doxorubicin hydrochloride, 10 mg
- J9003Leuprolide injectable (camcevi etm), 1 mg
- J9010Injection, alemtuzumab, 10 mgterminated
- J9011Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015Injection, aldesleukin, per single use vial
- J9017Injection, arsenic trioxide, 1 mg
- J9020Injection, asparaginase, not otherwise specified, 10,000 unitsterminated
- J9021Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022Injection, atezolizumab, 10 mg
- J9023Injection, avelumab, 10 mg
- J9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025Injection, azacitidine, 1 mg
- J9026Injection, tarlatamab-dlle, 1 mg
- J9027Injection, clofarabine, 1 mg
Questions about J9019
What is HCPCS code J9019?
J9019 is a HCPCS Level II code for injection, asparaginase (erwinaze), 1,000 iu. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J9019?
The CMS HCPCS file marks J9019 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is J9019 still valid?
No. J9019 was terminated on December 31, 2025 and should not be used on new claims.